Clinical trials recruiting for PDAC - Pancreatic Ductal Adenocarcinoma

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
  NCT07049055 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
  NCT06151223 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
  NCT07454642 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
  NCT07117045 · Phase: Not specified · Ages: 50 Years and older · Sex: All (male and female) · 5 locations
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 41 locations
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
  NCT07659639 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Functional, Personalised and Integrated Profiling of Biopsied Pancreatic Tumours (CancerProfile by FNB)
  NCT06666803 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
  NCT05132244 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
  NCT07262957 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
  NCT05845801 · Phase: Not specified · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
  NCT06122896 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
  NCT07252232 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 66 locations
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
  NCT04900818 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
  NCT07621718 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
  NCT06922591 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
  NCT05218889 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
  NCT05727020 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
  NCT07243262 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for PDAC - Pancreatic Ductal Adenocarcinoma often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for PDAC - Pancreatic Ductal Adenocarcinoma trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.